ClinicalTrials.gg
CompletedNCT01216397Updated Jun 27, 2014Results posted

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

A Phase 1 interventional study of Linagliptin/Metformin (standard batch) and Linagliptin/Metformin (side batch) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

The objective of the current study is to investigate the relative bioavailability of two different batches of a 2.5 mg linagliptin / 1000 mg metformin fixed dose combination tablet (FDC).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), clinical laboratory tests
  2. Age 21 to 50 years (incl.)
  3. (BMI) 18.5 to 29.9 kg/m2 (incl.)
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion criteria:

  1. Any finding of the medical examination (including BP, PR and ) deviating from normal and of clinical relevance
  2. Any evidence of a concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Surgery of the gastrointestinal tract (except appendectomy)
  5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  6. History of relevant orthostatic hypotension, fainting spells or blackouts
  7. Chronic or relevant acute infections
  8. History of relevant allergy or (including allergy to drug or its )
  9. Intake of drugs within one month or less than 10 half-lives of the respective drug prior to first study drug administration
  10. Participation in another trial with an drug within 2 months prior to administration or during the trial
  11. Smoker (more than 10 cigarettes or 3 cigars 3 pipes daily)
  12. Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in males)
  13. Drug abuse
  14. Blood donation (more than 100 mL within four weeks prior to day 1 of visit 2)
  15. Any laboratory value outside the reference range that is of clinical relevance
  16. Inability to comply with dietary regimen of trial site

    For female subjects of only:

  17. Positive pregnancy test, pregnancy or planning to become pregnant 1 month before study or within 2 months after study completion
  18. No adequate 1 month before study and until 2 month after study completion, e.g. not any of the following: implants, injectables, combined hormonal contraceptives, hormonal IUD (intrauterine device), sexual abstinence for at least 1 month prior to first study drug administration, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who do not have a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to use an additional barrier method (e.g. condom).
  19. Lactation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Linagliptin/Metformin (standard batch)

    Fixed dose combination tablet

    Drug: Linagliptin/Metformin (standard batch)

  • Experimental
    Linagliptin/Metformin (side batch)

    Fixed dose combination tablet

    Drug: Linagliptin/Metformin (side batch)

Interventions

06

What researchers measure

Primary outcomes

  1. Linagliptin: Maximum Measured Concentration (Cmax)

    Geometric mean of Cmax of Linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  2. Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)

    Geometric mean of AUC0-72 of Linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  3. Metformin: Cmax

    Geometric Mean of Cmax of Metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  4. Metformin: AUC0-tz

    Geometric Mean of AUC0-tz of Metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

Secondary outcomes

  1. Linagliptin: AUC0-infinity

    Geometric mean of AUC0-infinity of Linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  2. Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation

    Geometric Mean of percentage of AUCtz-∞ of linagliptin, where percentage is the unit of measurement.

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  3. Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)

    Median of the t_max of linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  4. Linagliptin: λz (Terminal Elimination Rate Constant in Plasma)

    Geometric mean of the λ_z of linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  5. t1/2 (Terminal Half-life of the Analyte in Plasma)

    Geometric mean of the t1/2 of linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  6. Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)

    Geometric mean of the MRTpo of linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  7. Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)

    Geometric mean of the CL/F of linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  8. Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)

    Geometric mean of the Vz/F of linagliptin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  9. Metformin: AUC0-infinity

    Geometric Mean of AUC0-infinity of Metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  10. Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation

    Geometric Mean of the percentage of AUCtz-infinity of Metformin, where percentage is the unit of measurement.

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  11. Metformin: Tmax

    Median of tmax of metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  12. Metformin: λz (Terminal Elimination Rate Constant in Plasma)

    Geometric mean of λz of metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  13. Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma)

    Geometric mean of t1/2 of metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  14. Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)

    Geometric mean of MRTpo of metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  15. Metformin: CL/F

    Geometric mean of CL/F of metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  16. Metformin: Vz/F

    Geometric mean of Vz/F of metformin

    Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2

  17. Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities

    12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities

    Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2

  18. Participants With Treatment Emergent Adverse Events

    Number of patients with treatment emergent AEs

    Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2

  19. Participants Who Discontinued the Trial Because of an Adverse Event

    Number of participants who discontinued the trial because of an adverse event

    Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2

  20. Assessment of Tolerability by the Investigator

    Qualitative variable assessing the tolerability by the investigator

    Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2

07

Results

Posted Apr 25, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestoneStandard Batch Then Side BatchSide Batch Then Standard Batch
Started2020
Completed2020
Not completed00
Washout (35 Days)
Participant flow — Washout (35 Days)
MilestoneStandard Batch Then Side BatchSide Batch Then Standard Batch
Started2020
Completed2020
Not completed00
Period 2
Participant flow — Period 2
MilestoneStandard Batch Then Side BatchSide Batch Then Standard Batch
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryLinagliptin: Maximum Measured Concentration (Cmax)

Geometric mean of Cmax of Linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · nmol/L
Linagliptin: Maximum Measured Concentration (Cmax)
nmol/LStandard BatchSide Batch
Linagliptin: Maximum Measured Concentration (Cmax)5.36 ± 20.35.39 ± 20.3
Statistical analysis
  • Standard Batch vs Side Batch · ANOVA · Adjusted gmean ratio: 99.4 · 90% CI 94.2 to 105.0
PrimaryArea Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)

Geometric mean of AUC0-72 of Linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · nmol*hr/L
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)
nmol*hr/LStandard BatchSide Batch
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)179 ± 21.6179 ± 20.5
Statistical analysis
  • Standard Batch vs Side Batch · ANOVA · Adjusted gmean ratio: 100.1 · 90% CI 96.1 to 104.2
SecondaryLinagliptin: AUC0-infinity

Geometric mean of AUC0-infinity of Linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · nmol*hr/L
Linagliptin: AUC0-infinity
nmol*hr/LStandard BatchSide Batch
Linagliptin: AUC0-infinity267 ± 25.4267 ± 23.6
Statistical analysis
  • Standard Batch vs Side Batch · ANOVA · Adjusted gmean ratio: 100.1 · 90% CI 94.7 to 105.8
SecondaryLinagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation

Geometric Mean of percentage of AUCtz-∞ of linagliptin, where percentage is the unit of measurement.

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · percentage
Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation
percentageStandard BatchSide Batch
Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation32.6 ± 17.532.1 ± 20.3
SecondaryLinagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)

Median of the t_max of linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Median · hr
Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)
hrStandard BatchSide Batch
Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)3.00 (0.667 to 6.02)3.00 (0.983 to 6.02)
SecondaryLinagliptin: λz (Terminal Elimination Rate Constant in Plasma)

Geometric mean of the λ_z of linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · 1/hr
Linagliptin: λz (Terminal Elimination Rate Constant in Plasma)
1/hrStandard BatchSide Batch
Linagliptin: λz (Terminal Elimination Rate Constant in Plasma)0.0153 ± 17.10.0152 ± 21.6
Secondaryt1/2 (Terminal Half-life of the Analyte in Plasma)

Geometric mean of the t1/2 of linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · hr
t1/2 (Terminal Half-life of the Analyte in Plasma)
hrStandard BatchSide Batch
t1/2 (Terminal Half-life of the Analyte in Plasma)45.4 ± 17.145.6 ± 21.6
SecondaryLinagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)

Geometric mean of the MRTpo of linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · hr
Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)
hrStandard BatchSide Batch
Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)64.6 ± 15.764.5 ± 19.5
SecondaryLinagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)

Geometric mean of the CL/F of linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · mL/min
Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)
mL/minStandard BatchSide Batch
Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)330 ± 25.4330 ± 23.6
SecondaryLinagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)

Geometric mean of the Vz/F of linagliptin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · Liter
Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)
LiterStandard BatchSide Batch
Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)1300 ± 22.81300 ± 24.6
PrimaryMetformin: Cmax

Geometric Mean of Cmax of Metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · ng/mL
Metformin: Cmax
ng/mLStandard BatchSide Batch
Metformin: Cmax1790 ± 23.01820 ± 25.5
Statistical analysis
  • Standard Batch vs Side Batch · ANOVA · Adjusted gmean ratio: 97.9 · 90% CI 92.5 to 103.7
PrimaryMetformin: AUC0-tz

Geometric Mean of AUC0-tz of Metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · ng*hr/mL
Metformin: AUC0-tz
ng*hr/mLStandard BatchSide Batch
Metformin: AUC0-tz12100 ± 21.412100 ± 19.4
Statistical analysis
  • Standard Batch vs Side Batch · ANOVA · Adjusted gmean ratio: 100.4 · 90% CI 95.7 to 105.4
SecondaryMetformin: AUC0-infinity

Geometric Mean of AUC0-infinity of Metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · ng*h/mL
Metformin: AUC0-infinity
ng*h/mLStandard BatchSide Batch
Metformin: AUC0-infinity12400 ± 21.212300 ± 19.9
Statistical analysis
  • Standard Batch vs Side Batch · ANOVA · Adjusted gmean ratio: 100.3 · 90% CI 95.7 to 105.2
SecondaryMetformin: Percentage of AUCtz-∞ Obtained by Extrapolation

Geometric Mean of the percentage of AUCtz-infinity of Metformin, where percentage is the unit of measurement.

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · percentage
Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation
percentageStandard BatchSide Batch
Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation1.51 ± 87.41.52 ± 97.0
SecondaryMetformin: Tmax

Median of tmax of metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Median · hr
Metformin: Tmax
hrStandard BatchSide Batch
Metformin: Tmax1.99 (0.667 to 4.02)2.00 (0.65 to 4.02)
SecondaryMetformin: λz (Terminal Elimination Rate Constant in Plasma)

Geometric mean of λz of metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · 1/hr
Metformin: λz (Terminal Elimination Rate Constant in Plasma)
1/hrStandard BatchSide Batch
Metformin: λz (Terminal Elimination Rate Constant in Plasma)0.0493 ± 71.00.0514 ± 84.3
SecondaryMetformin: t1/2 (Terminal Half-life of the Analyte in Plasma)

Geometric mean of t1/2 of metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · hr
Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma)
hrStandard BatchSide Batch
Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma)14.1 ± 71.013.5 ± 84.3
SecondaryMetformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)

Geometric mean of MRTpo of metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · hr
Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)
hrStandard BatchSide Batch
Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)8.27 ± 31.18.23 ± 36.9
SecondaryMetformin: CL/F

Geometric mean of CL/F of metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · mL/min
Metformin: CL/F
mL/minStandard BatchSide Batch
Metformin: CL/F1350 ± 21.21350 ± 19.9
SecondaryMetformin: Vz/F

Geometric mean of Vz/F of metformin

Time frame:
Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Reported as:
Geometric mean · Liter
Metformin: Vz/F
LiterStandard BatchSide Batch
Metformin: Vz/F1640 ± 74.31580 ± 82.4
SecondaryElectrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities

12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities

Time frame:
Day 1 to 4 for period 1, and day 36 to 39 for period 2
Reported as:
Number · Participants
Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities
ParticipantsStandard BatchSide Batch
Physical examination abnormalities00
Vital sign abnormalities00
ECG abnormalities00
Laboratory finding abnormalities00
SecondaryParticipants With Treatment Emergent Adverse Events

Number of patients with treatment emergent AEs

Time frame:
Day 1 to 4 for period 1, and day 36 to 39 for period 2
Reported as:
Number · Participants
Participants With Treatment Emergent Adverse Events
ParticipantsStandard BatchSide Batch
Headache69
Nausea01
Vomiting21
Fatigue10
SecondaryParticipants Who Discontinued the Trial Because of an Adverse Event

Number of participants who discontinued the trial because of an adverse event

Time frame:
Day 1 to 4 for period 1, and day 36 to 39 for period 2
Reported as:
Number · Participants
Participants Who Discontinued the Trial Because of an Adverse Event
ParticipantsStandard BatchSide Batch
Participants Who Discontinued the Trial Because of an Adverse Event00
SecondaryAssessment of Tolerability by the Investigator

Qualitative variable assessing the tolerability by the investigator

Time frame:
Day 1 to 4 for period 1, and day 36 to 39 for period 2
Reported as:
Number · Participants
Assessment of Tolerability by the Investigator
ParticipantsStandard BatchSide Batch
Good3940
Not satisfactory10

Adverse events

Collected over 4 days (period 1) + 4 days (treatment period 2). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard Batch—0/40 (0%)7/40 (17.5%)
Side Batch—0/40 (0%)11/40 (27.5%)
Most frequent other events
Most frequent other events
EventStandard BatchSide Batch
HeadacheNervous system disorders7/4011/40

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean36.8 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female20
Male20
Body mass index
Body mass index(kg/m^2)All Participants
Mean23.74 ± 2.74
08

Study locations

1 site
  • 1288.6.1 Boehringer Ingelheim Investigational Site
    Ingelheim, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010 and a primary completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2010
First posted
Oct 7, 2010
Start
Sep 2010
Primary completionActual
Dec 2010
Results first posted
Apr 25, 2012
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01216397
Responsible party
Sponsor
First posted
Oct 7, 2010
Start date
Sep 2010
Primary completion
Dec 2010
Results posted
Apr 25, 2012
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linagliptin · Metformin

Start the discussion